Evidence map›Paper›PMID 33370294›Full record

ArticlePloS one2020

Podocyte-specific knockout of the neonatal Fc receptor (FcRn) results in differential protection depending on the model of glomerulonephritis.

James F Dylewski, Pantipa Tonsawan, Gabriela Garcia, Linda Lewis, Judith Blaine

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. A Putative Role for TRPC6 in Immune-Mediated Kidney Injury.International journal of molecular sciences · 2023
    Review
  6. The therapeutic age of the neonatal Fc receptor.Nature reviews. Immunology · 2023
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

James F DylewskiDivision of Renal Disease and Hypertension, University of Colorado School of Medicine, Aurora, CO, United States of America.ORCID 0000-0002-8158-8605
Pantipa TonsawanDivision of Nephrology, Khon Kaen University, Khon Kaen, Thailand.
Gabriela GarciaDivision of Renal Disease and Hypertension, University of Colorado School of Medicine, Aurora, CO, United States of America.
Linda LewisDivision of Renal Disease and Hypertension, University of Colorado School of Medicine, Aurora, CO, United States of America.
Judith BlaineDivision of Renal Disease and Hypertension, University of Colorado School of Medicine, Aurora, CO, United States of America.
University of Colorado Denver · USDenver Health Medical Center · USKhon Kaen University · TH

Funding

TRAINING IN RENAL &ELECTROLYTE DISEASE &HYPERTENSIONT32DK007135 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JOHNSON, RICHARD JOSEPH, KENDRICK, JESSICA B · 1986 to 2024
$5.3M
The Dual Role of the Neonatal Fc Receptor (FcRn) in PodocytesR01DK104264 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BLAINE, JUDITH T., · 2015 to 2024
$3.1M
Reduction of kidney progressive fibrosis by A2A adenosine receptor activation: PR01DK082509 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GARCIA, GABRIELA E · 2011 to 2015
$1.3M
NIDDK NIH HHS R01 DK082509NIDDK NIH HHS R01 DK104264NIDDK NIH HHS T32 DK007135
6 · The paper itself

Abstract

Podocytes have been proposed to be antigen presenting cells (APCs). In traditional APCs, the neonatal Fc receptor (FcRn) is required for antigen presentation and global knockout of FcRn protects against glomerulonephritis. Since podocytes express FcRn, we sought to determine whether the absence of podocyte FcRn ameliorates immune-mediated disease. We examined MHCII and costimulatory markers expression in cultured wild type (WT) and FcRn knockout (KO) podocytes. Interferon gamma (IFNγ) induced MHCII expression in both WT and KO podocytes but did not change CD80 expression. Neither WT nor KO expressed CD86 or inducible costimulatory ligand (ICOSL) at baseline or with IFNγ. Using an antigen presentation assay, WT podocytes but not KO treated with immune complexes induced a modest increase in IL-2. Induction of the anti-glomerular basement membrane (anti-GBM) model resulted in a significant decrease in glomerular crescents in podocyte-specific FcRn knockout mouse (podFcRn KO) versus controls but the overall percentage of crescents was low. To examine the effects of the podocyte-specific FcRn knockout in a model with a longer autologous phase, we used the nephrotoxic serum nephritis (NTS) model. We found that the podFcRn KO mice had significantly reduced crescent formation and glomerulosclerosis compared to control mice. This study demonstrates that lack of podocyte FcRn is protective in immune mediated kidney disease that is dependent on an autologous phase. This study also highlights the difference between the anti-GBM model and NTS model of disease.

Indexed as

AnimalsCells, CulturedDisease Models, AnimalFlow CytometryGlomerular Basement MembraneGlomerulonephritisHistocompatibility Antigens Class IMiceMice, KnockoutPodocytesReceptors, FcFc receptor, neonatalHistocompatibility Antigens Class IReceptors, Fc

Identifiers

PMID33370294
PMCPMC7769425
OpenAlexW3114948426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.